BDBM298431 4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-methoxy-phenyl]carbamoylamino]-1-naphthyl]oxy]-2-pyridyl]amino]-2-methoxy-N-[(1-methyl-4-piperidyl)methyl]benzamide::US10125100, Example 17(ak)::US10392346, Example 17(ak)::US10941115, Example 17(ak)::US9751837, Example 17(ak)

SMILES: COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1

InChI Key: InChIKey=YBQBWKIOPABUPG-UHFFFAOYSA-N

Data: 12 IC50

Find this compound or compounds like it in BindingDB or PDB:

Substructure Similarity at least:  must be >=0.5 Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 298431   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human))	BDBM298431 (4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...) Show SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1 Show InChI InChI=1S/C43H51N7O7S/c1-43(2,3)28-22-35(40(56-6)36(23-28)49-58(7,53)54)48-42(52)47-34-14-15-37(32-11-9-8-10-31(32)34)57-30-16-19-44-39(25-30)46-29-12-13-33(38(24-29)55-5)41(51)45-26-27-17-20-50(4)21-18-27/h8-16,19,22-25,27,49H,17-18,20-21,26H2,1-7H3,(H,44,46)(H,45,51)(H2,47,48,52)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	12	n/a	n/a	n/a	n/a	n/a	n/a
Topivert Pharma Limited US Patent					Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...				US Patent US10125100 (2018) BindingDB Entry DOI: 10.7270/Q2XW4MV4
					More data for this Ligand-Target Pair
Tyrosine-protein kinase SYK (Homo sapiens (Human))	BDBM298431 (4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...) Show SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1 Show InChI InChI=1S/C43H51N7O7S/c1-43(2,3)28-22-35(40(56-6)36(23-28)49-58(7,53)54)48-42(52)47-34-14-15-37(32-11-9-8-10-31(32)34)57-30-16-19-44-39(25-30)46-29-12-13-33(38(24-29)55-5)41(51)45-26-27-17-20-50(4)21-18-27/h8-16,19,22-25,27,49H,17-18,20-21,26H2,1-7H3,(H,44,46)(H,45,51)(H2,47,48,52)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	85	n/a	n/a	n/a	n/a	n/a	n/a
Topivert Pharma Limited US Patent					Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...				US Patent US10125100 (2018) BindingDB Entry DOI: 10.7270/Q2XW4MV4
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 (Homo sapiens (Human))	BDBM298431 (4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...) Show SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1 Show InChI InChI=1S/C43H51N7O7S/c1-43(2,3)28-22-35(40(56-6)36(23-28)49-58(7,53)54)48-42(52)47-34-14-15-37(32-11-9-8-10-31(32)34)57-30-16-19-44-39(25-30)46-29-12-13-33(38(24-29)55-5)41(51)45-26-27-17-20-50(4)21-18-27/h8-16,19,22-25,27,49H,17-18,20-21,26H2,1-7H3,(H,44,46)(H,45,51)(H2,47,48,52)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.82E+3	n/a	n/a	n/a	n/a	n/a	n/a
Topivert Pharma Limited US Patent					Assay Description The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...				US Patent US10125100 (2018) BindingDB Entry DOI: 10.7270/Q2XW4MV4
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human))	BDBM298431 (4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...) Show SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1 Show InChI InChI=1S/C43H51N7O7S/c1-43(2,3)28-22-35(40(56-6)36(23-28)49-58(7,53)54)48-42(52)47-34-14-15-37(32-11-9-8-10-31(32)34)57-30-16-19-44-39(25-30)46-29-12-13-33(38(24-29)55-5)41(51)45-26-27-17-20-50(4)21-18-27/h8-16,19,22-25,27,49H,17-18,20-21,26H2,1-7H3,(H,44,46)(H,45,51)(H2,47,48,52)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	12	n/a	n/a	n/a	n/a	n/a	n/a
RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED US Patent					Assay Description The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...				US Patent US9751837 (2017) BindingDB Entry DOI: 10.7270/Q2028TP7
					More data for this Ligand-Target Pair
Tyrosine-protein kinase SYK (Homo sapiens (Human))	BDBM298431 (4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...) Show SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1 Show InChI InChI=1S/C43H51N7O7S/c1-43(2,3)28-22-35(40(56-6)36(23-28)49-58(7,53)54)48-42(52)47-34-14-15-37(32-11-9-8-10-31(32)34)57-30-16-19-44-39(25-30)46-29-12-13-33(38(24-29)55-5)41(51)45-26-27-17-20-50(4)21-18-27/h8-16,19,22-25,27,49H,17-18,20-21,26H2,1-7H3,(H,44,46)(H,45,51)(H2,47,48,52)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	85	n/a	n/a	n/a	n/a	n/a	n/a
RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED US Patent					Assay Description Method 1The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the...				US Patent US9751837 (2017) BindingDB Entry DOI: 10.7270/Q2028TP7
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 (Homo sapiens (Human))	BDBM298431 (4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...) Show SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1 Show InChI InChI=1S/C43H51N7O7S/c1-43(2,3)28-22-35(40(56-6)36(23-28)49-58(7,53)54)48-42(52)47-34-14-15-37(32-11-9-8-10-31(32)34)57-30-16-19-44-39(25-30)46-29-12-13-33(38(24-29)55-5)41(51)45-26-27-17-20-50(4)21-18-27/h8-16,19,22-25,27,49H,17-18,20-21,26H2,1-7H3,(H,44,46)(H,45,51)(H2,47,48,52)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.82E+3	n/a	n/a	n/a	n/a	n/a	n/a
Oxular Acquisitions Limited US Patent					Assay Description GSK 3α Method 2: The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by d...				US Patent US10941115 (2021)
					More data for this Ligand-Target Pair
Proto-oncogene tyrosine-protein kinase Src (Homo sapiens (Human))	BDBM298431 (4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...) Show SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1 Show InChI InChI=1S/C43H51N7O7S/c1-43(2,3)28-22-35(40(56-6)36(23-28)49-58(7,53)54)48-42(52)47-34-14-15-37(32-11-9-8-10-31(32)34)57-30-16-19-44-39(25-30)46-29-12-13-33(38(24-29)55-5)41(51)45-26-27-17-20-50(4)21-18-27/h8-16,19,22-25,27,49H,17-18,20-21,26H2,1-7H3,(H,44,46)(H,45,51)(H2,47,48,52)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	12	n/a	n/a	n/a	n/a	n/a	n/a
Topivert Pharma Limited US Patent					Assay Description c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...				US Patent US10392346 (2019) BindingDB Entry DOI: 10.7270/Q2N018WV
					More data for this Ligand-Target Pair
Tyrosine-protein kinase SYK (Homo sapiens (Human))	BDBM298431 (4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...) Show SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1 Show InChI InChI=1S/C43H51N7O7S/c1-43(2,3)28-22-35(40(56-6)36(23-28)49-58(7,53)54)48-42(52)47-34-14-15-37(32-11-9-8-10-31(32)34)57-30-16-19-44-39(25-30)46-29-12-13-33(38(24-29)55-5)41(51)45-26-27-17-20-50(4)21-18-27/h8-16,19,22-25,27,49H,17-18,20-21,26H2,1-7H3,(H,44,46)(H,45,51)(H2,47,48,52)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	85	n/a	n/a	n/a	n/a	n/a	n/a
Topivert Pharma Limited US Patent					Assay Description c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...				US Patent US10392346 (2019) BindingDB Entry DOI: 10.7270/Q2N018WV
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 (Homo sapiens (Human))	BDBM298431 (4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...) Show SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1 Show InChI InChI=1S/C43H51N7O7S/c1-43(2,3)28-22-35(40(56-6)36(23-28)49-58(7,53)54)48-42(52)47-34-14-15-37(32-11-9-8-10-31(32)34)57-30-16-19-44-39(25-30)46-29-12-13-33(38(24-29)55-5)41(51)45-26-27-17-20-50(4)21-18-27/h8-16,19,22-25,27,49H,17-18,20-21,26H2,1-7H3,(H,44,46)(H,45,51)(H2,47,48,52)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.82E+3	n/a	n/a	n/a	n/a	n/a	n/a
Topivert Pharma Limited US Patent					Assay Description GSK 3α Method 2: This method follows the same steps as Method 1, but utilises a shorter period of mixing of the test compound (105 minutes inste...				US Patent US10392346 (2019) BindingDB Entry DOI: 10.7270/Q2N018WV
					More data for this Ligand-Target Pair
Protein cereblon/Tyrosine-protein kinase SRC (Homo sapiens (Human))	BDBM298431 (4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...) Show SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1 Show InChI InChI=1S/C43H51N7O7S/c1-43(2,3)28-22-35(40(56-6)36(23-28)49-58(7,53)54)48-42(52)47-34-14-15-37(32-11-9-8-10-31(32)34)57-30-16-19-44-39(25-30)46-29-12-13-33(38(24-29)55-5)41(51)45-26-27-17-20-50(4)21-18-27/h8-16,19,22-25,27,49H,17-18,20-21,26H2,1-7H3,(H,44,46)(H,45,51)(H2,47,48,52)	PDB MMDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	12	n/a	n/a	n/a	n/a	n/a	n/a
Oxular Acquisitions Limited US Patent					Assay Description c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...				US Patent US10941115 (2021)
					More data for this Ligand-Target Pair
Tyrosine-protein kinase SYK (Homo sapiens (Human))	BDBM298431 (4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...) Show SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1 Show InChI InChI=1S/C43H51N7O7S/c1-43(2,3)28-22-35(40(56-6)36(23-28)49-58(7,53)54)48-42(52)47-34-14-15-37(32-11-9-8-10-31(32)34)57-30-16-19-44-39(25-30)46-29-12-13-33(38(24-29)55-5)41(51)45-26-27-17-20-50(4)21-18-27/h8-16,19,22-25,27,49H,17-18,20-21,26H2,1-7H3,(H,44,46)(H,45,51)(H2,47,48,52)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	85	n/a	n/a	n/a	n/a	n/a	n/a
Oxular Acquisitions Limited US Patent					Assay Description c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...				US Patent US10941115 (2021)
					More data for this Ligand-Target Pair
Glycogen synthase kinase-3 (Homo sapiens (Human))	BDBM298431 (4-[[4-[[4-[[5-tert-butyl-3-(methanesulfonamido)-2-...) Show SMILES COc1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(NS(C)(=O)=O)c4OC)C(C)(C)C)c4ccccc34)ccn2)ccc1C(=O)NCC1CCN(C)CC1 Show InChI InChI=1S/C43H51N7O7S/c1-43(2,3)28-22-35(40(56-6)36(23-28)49-58(7,53)54)48-42(52)47-34-14-15-37(32-11-9-8-10-31(32)34)57-30-16-19-44-39(25-30)46-29-12-13-33(38(24-29)55-5)41(51)45-26-27-17-20-50(4)21-18-27/h8-16,19,22-25,27,49H,17-18,20-21,26H2,1-7H3,(H,44,46)(H,45,51)(H2,47,48,52)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt UniProtKB/TrEMBL B.MOAD antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	1.82E+3	n/a	n/a	n/a	n/a	n/a	n/a
RESPIVERT LIMITED; TOPIVERT PHARMA LIMITED US Patent									US Patent US9751837 (2017) BindingDB Entry DOI: 10.7270/Q2028TP7
					More data for this Ligand-Target Pair